TY - JOUR
T1 - Atomic insights into ML-SI3 mediated human TRPML1 inhibition
AU - Schmiege, Philip
AU - Fine, Michael
AU - Li, Xiaochun
N1 - Funding Information:
M.F. was partially supported by the Casma Therapeutics, and X.L. receives consultant income and holds shares from Casma Therapeutics on the study of TRPML1.
Funding Information:
The data were collected at the UT Southwestern Medical Center; we thank D. Stoddard for assistance in data collection. We thank J. Fortanet and A. Jha (Casma Therapeutics) for providing the ML-SI3 and HEK293-tet-TRPML1-L/A cell line. This work was supported by NIH grant R01 GM135343 and the Endowed Scholars Program in Medical Science of UT Southwestern Medical Center (to X.L.). P.S. is supported by NIH T32GM131963 . X.L. is a Damon Runyon-Rachleff Innovator supported by the Damon Runyon Cancer Research Foundation ( DRR-53S-19 ) and a Rita C. and William P. Clements Jr. Scholar in Biomedical Research at UT Southwestern Medical Center .
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/11/4
Y1 - 2021/11/4
N2 - Transient receptor potential mucolipin 1 (TRPML1) regulates lysosomal calcium signaling, lipid trafficking, and autophagy-related processes. This channel is regulated by phosphoinositides and the low pH environment of the lysosome, maintaining calcium levels essential for proper lysosomal function. Recently, several small molecules specifically targeting the TRPML family have been demonstrated to modulate channel activity. One of these, a synthetic antagonist ML-SI3, can prevent lysosomal calcium efflux and has been reported to block downstream TRPML1-mediated induction of autophagy. Here, we report a cryo–electron microscopy structure of human TRPML1 with ML-SI3 at 2.9-Å resolution. ML-SI3 binds to the hydrophobic cavity created by S5, S6, and PH1, the same cavity where the synthetic agonist ML-SA1 binds. Electrophysiological characterizations show that ML-SI3 can compete with ML-SA1, blocking channel activation yet does not inhibit PI(3,5)P2-dependent activation of the channel. Consequently, this work provides molecular insight into how ML-SI3 and native lipids regulate TRPML1 activity.
AB - Transient receptor potential mucolipin 1 (TRPML1) regulates lysosomal calcium signaling, lipid trafficking, and autophagy-related processes. This channel is regulated by phosphoinositides and the low pH environment of the lysosome, maintaining calcium levels essential for proper lysosomal function. Recently, several small molecules specifically targeting the TRPML family have been demonstrated to modulate channel activity. One of these, a synthetic antagonist ML-SI3, can prevent lysosomal calcium efflux and has been reported to block downstream TRPML1-mediated induction of autophagy. Here, we report a cryo–electron microscopy structure of human TRPML1 with ML-SI3 at 2.9-Å resolution. ML-SI3 binds to the hydrophobic cavity created by S5, S6, and PH1, the same cavity where the synthetic agonist ML-SA1 binds. Electrophysiological characterizations show that ML-SI3 can compete with ML-SA1, blocking channel activation yet does not inhibit PI(3,5)P2-dependent activation of the channel. Consequently, this work provides molecular insight into how ML-SI3 and native lipids regulate TRPML1 activity.
KW - ML-SI3
KW - PIP2
KW - TRPML1
KW - cryo-EM
KW - electrophysiology
UR - http://www.scopus.com/inward/record.url?scp=85118495052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118495052&partnerID=8YFLogxK
U2 - 10.1016/j.str.2021.06.003
DO - 10.1016/j.str.2021.06.003
M3 - Article
C2 - 34171299
AN - SCOPUS:85118495052
SN - 0969-2126
VL - 29
SP - 1295-1302.e3
JO - Structure with Folding & design
JF - Structure with Folding & design
IS - 11
ER -